Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN FE 1.5/30 vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years (if no known contraindications and have achieved menarche),Off-label: Dysmenorrhea, menstrual irregularities, endometriosis-associated pain, hirsutism
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Ethinyl estradiol terminal half-life is approximately 13-17 hours; norethindrone terminal half-life is approximately 7-10 hours. Steady-state is reached within 5-10 days.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Ethinyl estradiol: primarily CYP3A4 metabolism with first-pass hepatic and intestinal metabolism; undergoes conjugation (glucuronidation and sulfation). Norethindrone: extensively metabolized via reduction, glucuronidation, and sulfation; CYP3A4 also involved.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Ethinyl estradiol and norethindrone are primarily excreted via renal (urine) and fecal routes. Approximately 40-50% of ethinyl estradiol is excreted renally as metabolites, with 20-30% in feces. Norethindrone metabolites are excreted ~50-70% renally and 20-30% fecally. Less than 5% is excreted unchanged.
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Ethinyl estradiol: ~97-98% bound, primarily to albumin (70%) and sex hormone-binding globulin (SHBG). Norethindrone: ~61-63% bound, primarily to albumin and SHBG.
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
Ethinyl estradiol: Vd approximately 2.5-4 L/kg; norethindrone: Vd approximately 4-5 L/kg. Distribution into breast milk and body fat is notable.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Ethinyl estradiol: ~40-50% due to first-pass metabolism; norethindrone: ~50-65% with first-pass metabolism. Food may increase bioavailability.
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
Contraindicated in patients with renal impairment or renal disease.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). Use with caution in Child-Pugh class A, consider alternative therapy.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Not indicated for use in pediatric females before menarche. For postmenarchal pediatric patients, dosage same as adults: one tablet orally once daily for 21 days, then 7 placebo tablets.
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Not indicated for use in postmenopausal women. Safety and efficacy not established in geriatric population.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular events (stroke, myocardial infarction, thromboembolism) from combined oral contraceptives. Risk increases with age and number of cigarettes smoked, particularly in women >35 years. Advise not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Increased risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, especially in smokers >35 years, hypertension, obesity, diabetes, hyperlipidemia, or migraine with aura. Monitor for undiagnosed abnormal genital bleeding, liver disease, hypertension, depression, migraine, carbohydrate/lipid effects, hereditary angioedema, chloasma, retinal thrombosis, gallbladder disease, and anaphylactic reactions. Discontinue if jaundice, vision changes, or severe headache occurs.
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Current or history of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, or transient ischemic attack; known coagulation disorders; valvular heart disease with complications; uncontrolled hypertension; diabetes with vascular involvement; headache with focal neurological symptoms (migraine with aura) in women >35; estrogen-sensitive cancer (e.g., breast cancer); hepatic tumors or active liver disease; undiagnosed abnormal uterine bleeding; pregnancy; hypersensitivity to components; cigarette smoking in women >35 years; use with hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir).
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
Grapefruit or grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; avoid concurrent consumption. No specific dietary restrictions otherwise. Iron supplement in active tablets may cause GI upset; take with food to reduce irritation.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
No increased risk of birth defects observed with oral contraceptives; avoid use in pregnancy due to potential for fetal harm and lack of necessity. First trimester: no consistent evidence of malformations. Second/third trimester: may cause fetal harm from estrogenic effects; discontinue if pregnancy occurs.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Small amounts of ethinyl estradiol and norethindrone pass into breast milk; M/P ratio not established. May reduce milk quantity and quality. Not recommended for breastfeeding mothers until weaning complete to avoid infant exposure to sex hormones.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Contraindicated in pregnancy; no dose adjustment applicable. Pharmacokinetic changes in pregnancy (increased clearance) may reduce efficacy if used inadvertently; use alternative contraception.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
Contains norethindrone 1.5 mg and ethinyl estradiol 30 mcg; low estrogen dose, suitable for women with estrogen sensitivity; iron supplement (ferrous fumarate 75 mg) in last 7 tablets helps prevent iron deficiency; missed pill protocol: if one tablet missed, take as soon as remembered; if two missed in week 1 or 2, take two the next day and two the day after; if two missed in week 3 or three or more missed at any time, discard pack and start new pack next day, use backup contraception for 7 days.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take one tablet daily at the same time, preferably after an evening meal to reduce nausea.,The last 7 tablets (brown) contain iron; do not skip them even if bleeding occurs.,If you miss a pill, refer to the missed pill instructions in the package insert.,Use backup contraception (e.g., condoms) if pills are missed or if you start a new pack late.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first 3 months.,Report severe abdominal pain, chest pain, shortness of breath, severe headache, or vision changes immediately.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,This medication does not protect against sexually transmitted infections (STIs).
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN FE 1.5/30 vs DESOGEN, answered by our medical review team.
LARIN FE 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN FE 1.5/30 and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN FE 1.5/30 is: One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN FE 1.5/30 and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN FE 1.5/30 is classified as Category C. No increased risk of birth defects observed with oral contraceptives; avoid use in pregnancy due to potential for fetal harm and lack of necessity. First trimester: no consistent e. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.